TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

HY4PET

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

HY4PET

ST13

US500000079354552

Classe

5, 10, 44

Pedido

79354552

Registro

7369549

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

35

Atualização mais recente

01/12/2025

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

5, 10, 44

Data de depósito

17/08/2022

Data de registro

30/04/2024

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

30/04/2024

Última transação

01/12/2025

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

99

Localização do titular

NL

Examinador

FRENCH,CURTIS W

Unidade examinadora

M60

Localização atual

FILE REPOSITORY (FRANCONIA)

Titulares e representantes

Titulares

Hy2Care B.V.

Representantes

Bradley M. Stohry Reichel Stohry Dean LLP

Classificação técnica

Classes Nice

Classe 5Classe 10Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceutical compositions for cartilage repair and treatments; pharmaceutical compositions for pain management and inflammation reduction; pharmaceutical compositions for bone repair; pharmaceutical gels for cartilage repair and treatments; pharmaceutical gels for pain management and inflammation reduction; pharmaceutical gels for bone repair; injectable pharmaceuticals for cartilage repair and treatments; injectable pharmaceuticals for pain management and inflammation reduction; injectable pharmaceuticals for bone repair; pharmaceutical products containing liquid polymers for cartilage repair and treatments; pharmaceutical products containing liquid polymers for pain management and inflammation reduction; pharmaceutical products containing liquid polymers for bone repair; pharmaceutical products containing hydrogels for cartilage repair and treatments; pharmaceutical products containing hydrogels for pain management and inflammation reduction; pharmaceutical products containing hydrogels for bone repair; advanced therapy medicinal products for cartilage repair and treatments; advanced therapy medicinal products for pain management and inflammation reduction; advanced therapy medicinal products for bone repair; advanced therapy medicinal products containing liquid polymers for cartilage repair and treatments; advanced therapy medicinal products containing liquid polymers for pain management and inflammation reduction; advanced therapy medicinal products containing liquid polymers for bone repair; advanced therapy medicinal products containing hydrogels for cartilage repair and treatments; advanced therapy medicinal products containing hydrogels for pain management and inflammation reduction; advanced therapy medicinal products containing hydrogels for bone repair; biological tissue cultures for medical purposes; biological tissue cultures for veterinary purposes; medicated hydrogels for cartilage repair and treatments; medicated hydrogels for pain management and inflammation reduction; medicated hydrogels for bone repair; medicated hydrogels resorbable by the animal body for cartilage repair and treatments; medicated hydrogels resorbable by the animal body for pain management and inflammation reduction; medicated hydrogels resorbable by the animal body for bone repair; pharmaceutical products for cartilage repair and treatments; pharmaceutical products for pain management and inflammation reduction; pharmaceutical products for bone repair; injectable dermal fillers; dental fillers, namely, teeth filling material; surgical glues and sealants

Classe 10

Medical devices, namely, injection needles; medical devices, namely, syringes; medical devices for injection of liquid components in the animal body, namely, injection needles; medical devices for injection of liquid polymers in the animal body, namely, injection needles; medical devices for injection of hydrogels in the animal body, namely, injection needles; medical devices for supply of pharmaceutical products for cartilage repair to the animal body, namely, injection instruments with needles; medical devices for supply of pharmaceutical products for bone repair to the animal body, namely, injection instruments with needles; medical devices for supply of dental fillers to the animal body, namely, injection needles; medical devices for supply of dental fillers to the animal body, namely, syringes; medical devices for application of surgical glues and sealants to the animal body; diagnostic apparatus for medical purposes, namely, ultrasound diagnostic apparatus; diagnostic apparatus for medical purposes, namely, X-ray diagnostic apparatus; cell culture instruments for medical use, namely, cell culture chambers

Classe 44

Medical services, namely, cartilage repair in the animal body; medical services, namely, pain management and inflammation reduction in the animal body; medical services, namely, bone repair in the animal body; dermatology services for the animal body; dentistry services for the animal body; veterinary dentistry services; surgical treatment services, namely, surgery of the animal body; veterinary surgical services; medical services for the diagnosis of conditions of the animal body; drug screening of the animal body for medical purposes; drug screening of the animal body for medical purposes involving application of liquid polymers; drug screening of the animal body for medical purposes involving application of hydrogels

Publicações

Histórico de despachos e eventos da marca no USPTO.

35 publicações encontradas

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

30/11/2025

FICS

FINAL DISPOSITION NOTICE SENT TO IB

09/11/2025

FIMP

FINAL DISPOSITION PROCESSED

08/11/2025

NREP

NEW REPRESENTATIVE AT IB RECEIVED

24/10/2025

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

07/06/2025

NREP

NEW REPRESENTATIVE AT IB RECEIVED

06/06/2025

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

21/04/2025

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

21/04/2025

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

21/04/2025

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

21/04/2025

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

21/04/2025

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

30/04/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

30/04/2024

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

29/04/2024

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

10/04/2024

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

10/04/2024

GPNX

NOTIFICATION PROCESSED BY IB

14/02/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

13/02/2024

PUBO

PUBLISHED FOR OPPOSITION

13/02/2024

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

24/01/2024

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

24/01/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

24/01/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

05/01/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

28/12/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

27/12/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

27/12/2023

RFNT

REFUSAL PROCESSED BY IB

01/08/2023

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

12/07/2023

RFRR

REFUSAL PROCESSED BY MPU

12/07/2023

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

08/06/2023

CNRT

NON-FINAL ACTION WRITTEN

07/06/2023

DOCK

ASSIGNED TO EXAMINER

05/06/2023

MAFR

APPLICATION FILING RECEIPT MAILED

18/11/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

14/11/2022

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

10/11/2022

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace HY4PET ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.